Malta - İngilizce - Malta Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - salmeterol xinafoate, fluticasone propionate - inhalation powder, pre-dispensed - fluticasone propionate 250 µg salmeterol xinafoate 50 µg - drugs for obstructive airway diseases

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - salmeterol and fluticasone

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - salmeterol; fluticasone propionate - inhalation powder, pre-dispensed - salmeterol and fluticasone

Malta - İngilizce - Malta Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - inhalation powder, pre-dispensed - salmeterol xinafoate 50 µg fluticasone propionate 250 µg - drugs for obstructive airway diseases

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

b & s healthcare - salmeterol xinafoate, fluticasone propionate - powder for inhalation - 50/500 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

ltt pharma limited - fluticasone propionate; salmeterol xinafoate - powder for inhalation - 50/100 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

Güney Afrika - İngilizce - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - tablet - see ingredients - each blister contains fluticasone propionate 500,0 ug salmeterol xinafoate equivalent to salmeterol 50,0 ug

Ermenistan - İngilizce - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - salmeterol (salmeterol xinafoate), fluticasone (fluticasone propionate) - powder for inhalation - 50mcg+100mcg

Ermenistan - İngilizce - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - salmeterol (salmeterol xinafoate), fluticasone (fluticasone propionate) - powder for inhalation - 50mcg+250mcg

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.